CTSO · Annual Report (Form 10-K) · Filed March 30, 2026

Cytosorbents Corp — 10-K exhibit

ctso-20251231xex24d1.htm

Exhibit 24.1

Power of Attorney

Each director and/or officer of CytoSorbents Corporation (the “Corporation”) whose signature appears below hereby appoints Phillip P. Chan or Peter J. Mariani as his or her attorneys or either of them individually as his or her attorney, to sign, in his or her name and behalf and in any and all capacities stated below, and to cause to be filed with the Securities and Exchange Commission (the “Commission”), the Corporation’s Annual Report on Form 10-K (the “Form 10-K”) for the year ended December 31, 2025, and likewise to sign and file with the Commission any and all amendments to the Form 10-K, and the Corporation hereby appoints such persons as its attorneys-in-fact and each of them as its attorney-in-fact with like authority to sign and file the Form 10-K and any amendments thereto granting to each such attorney-in-fact full power of substitution and revocation, and hereby ratifying all that any such attorney-in-fact or his substitute may do by virtue hereof.

IN WITNESS WHEREOF, we have hereunto set our hands as of March 29, 2026.


Signature		Title

/s/ Dr. Phillip P. Chan		Chief Executive Officer and Director
Dr. Phillip P. Chan		(Principal Executive Officer)

/s/ Peter J. Mariani		Chief Financial Officer
Peter J. Mariani		(Principal Financial Officer)

/s/ Michael G. Bator		Chairman of the Board
Michael G. Bator

/s/ Alan D. Sobel		Director
Alan D. Sobel

/s/ Edward R. Jones		Director
Edward R. Jones

/s/ Jiny Kim		Director
Jiny Kim

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer